Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group

Leukemia & Lymphoma
Meletios A DimopoulosHellenic Cooperative Oncology Group

Abstract

The treatment of patients with recurrent low-grade lymphoma with the combination of fludarabine, mitoxantrone and dexamethasone has been associated with significant activity but has also caused frequent infectious complications. We designed a phase II study for previously untreated patients with the combination of fludarabine and mitoxantrone but without steroids. Our aim was to assess the activity of this combination as primary treatment for low-grade lymphoma and to avoid the additional immunosuppression induced by dexamethasone. Twenty seven patients with low-grade lymphoma received fludarabine 25 mg/m2/day i.v. on days 1-3 and mitoxantrone 10 mg/m2 i.v. on day 1. The treatment was repeated every 28 days for a maximum of six cycles. Twenty patients (74%) achieved an objective response including 12 (44%) complete and 8 (30%) partial responses. The main toxicity was grade III or IV neutropenia, which occurred in 40% of patients but there were no severe opportunistic infections. The median time to progression for all patients was 32 months. With a median follow-up of 33.4 months, six patients have died and the probability of survival at 3 years is 75%. We conclude that the fludarabine and mitoxantrone regimen is safe and effect...Continue Reading

References

May 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R RedmanM J Keating
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S HochsterM J O'Connell
Jan 1, 1981·Cancer·A B MillerA Winkler
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinM Keating
Aug 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniR Fanin
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Solal-CélignyM Leporrier
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinF Cabanillas
May 11, 1999·Hematological Oncology·C EmmanouilidesL Kunkel
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P L ZinzaniS Tura
May 16, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniS Tura
Sep 21, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C R CrawleyT A Lister

❮ Previous
Next ❯

Citations

Jan 14, 2003·Hematological Oncology
Mar 22, 2006·Seminars in Hematology·Nicholas Di Bella, Farhad Ravandi
Jun 6, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.